Market Closed -
Canadian Securities Exchange
12:01:09 2024-06-28 EDT
|
5-day change
|
1st Jan Change
|
0.025
CAD
|
-16.67%
|
|
-44.44%
|
-28.57%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
6.946
|
4.647
|
10.43
|
1.762
|
0.7344
|
1.186
|
Enterprise Value (EV)
1 |
5.254
|
3.897
|
8.89
|
1.115
|
0.7466
|
1.33
|
P/E ratio
|
-9.51
x
|
-3.87
x
|
-7.99
x
|
-0.74
x
|
-0.92
x
|
-1.31
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
72
x
|
15.4
x
|
13.9
x
|
7.84
x
|
5.32
x
|
19.2
x
|
EV / Revenue
|
54.5
x
|
12.9
x
|
11.9
x
|
4.96
x
|
5.4
x
|
21.5
x
|
EV / EBITDA
|
-
|
-4,673,545
x
|
-9,509,622
x
|
-735,205
x
|
-1,010,722
x
|
-1,740,923
x
|
EV / FCF
|
-31.5
x
|
-5.73
x
|
-8.64
x
|
-6.08
x
|
-2.22
x
|
-56.1
x
|
FCF Yield
|
-3.18%
|
-17.5%
|
-11.6%
|
-16.5%
|
-45.1%
|
-1.78%
|
Price to Book
|
3.17
x
|
3.14
x
|
3.35
x
|
2.5
x
|
-8.86
x
|
-1.82
x
|
Nbr of stocks (in thousands)
|
23,153
|
23,235
|
29,375
|
29,375
|
29,375
|
33,895
|
Reference price
2 |
0.3000
|
0.2000
|
0.3550
|
0.0600
|
0.0250
|
0.0350
|
Announcement Date
|
4/30/19
|
4/29/20
|
4/30/21
|
5/2/22
|
5/1/23
|
5/7/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.0964
|
0.3024
|
0.75
|
0.2249
|
0.1382
|
0.0619
|
EBITDA
|
-
|
-0.8339
|
-0.9348
|
-1.516
|
-0.7387
|
-0.764
|
EBIT
1 |
-0.4127
|
-0.8365
|
-0.9434
|
-1.525
|
-0.7454
|
-0.7672
|
Operating Margin
|
-428.09%
|
-276.63%
|
-125.79%
|
-677.71%
|
-539.55%
|
-1,238.82%
|
Earnings before Tax (EBT)
1 |
-0.5084
|
-0.8359
|
-1.185
|
-2.394
|
-0.7941
|
-0.8131
|
Net income
1 |
-0.5084
|
-0.8359
|
-1.185
|
-2.394
|
-0.7941
|
-0.8131
|
Net margin
|
-527.35%
|
-276.45%
|
-157.98%
|
-1,064.14%
|
-574.76%
|
-1,312.93%
|
EPS
2 |
-0.0315
|
-0.0517
|
-0.0444
|
-0.0815
|
-0.0270
|
-0.0268
|
Free Cash Flow
1 |
-0.167
|
-0.6805
|
-1.029
|
-0.1834
|
-0.3364
|
-0.0237
|
FCF margin
|
-173.26%
|
-225.05%
|
-137.16%
|
-81.55%
|
-243.51%
|
-38.26%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/30/19
|
4/29/20
|
4/30/21
|
5/2/22
|
5/1/23
|
5/7/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
0.01
|
0.14
|
Net Cash position
1 |
1.69
|
0.75
|
1.54
|
0.65
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.0166
x
|
-0.1882
x
|
Free Cash Flow
1 |
-0.17
|
-0.68
|
-1.03
|
-0.18
|
-0.34
|
-0.02
|
ROE (net income / shareholders' equity)
|
-36.9%
|
-45.6%
|
-51.7%
|
-126%
|
-255%
|
221%
|
ROA (Net income/ Total Assets)
|
-14.2%
|
-22.9%
|
-23.2%
|
-47.4%
|
-107%
|
-528%
|
Assets
1 |
3.572
|
3.65
|
5.116
|
5.052
|
0.7455
|
0.1541
|
Book Value Per Share
2 |
0.0900
|
0.0600
|
0.1100
|
0.0200
|
-0
|
-0.0200
|
Cash Flow per Share
2 |
0.0200
|
0.0200
|
0.0100
|
0.0200
|
0
|
0
|
Capex
|
-
|
0.03
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
10.47%
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/30/19
|
4/29/20
|
4/30/21
|
5/2/22
|
5/1/23
|
5/7/24
|
|
1st Jan change
|
Capi.
|
---|
| -28.57% | 644K | | -20.98% | 1.02B | | -15.70% | 136M | | +2.03% | 58.2M | | -22.22% | 56.93M |
Bio Medical Devices
|